礼来公司首席财务官Lucas Montarce表示,一旦获得美国食品药品监督管理局(FDA)的批准,该公司准备最早于今年第二季度在美国推出其新型口服减肥药orforglipron。审查工作正按预期进行,公司仍对FDA将在4月份做出决定“有信心”。
礼来公司首席财务官Lucas Montarce表示,一旦获得美国食品药品监督管理局(FDA)的批准,该公司准备最早于今年第二季度在美国推出其新型口服减肥药orforglipron。审查工作正按预期进行,公司仍对FDA将在4月份做出决定“有信心”。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.